Breast Cancer Clinical Trial
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant monotherapy. The study population is comprised of adults with HR+HER2- aBC. Patients will self-administer NUV-422 orally in 28-day cycles and receive 500 mg fulvestrant intramuscularly (IM) on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.
Men and women with diagnosis of locally advanced inoperable or metastatic HR+HER2- breast cancer
Evidence of disease progression on immediate prior therapy as determined by the Investigator per standard criteria
Patients must have received standard of care treatments for their breast cancer and be eligible to receive fulvestrant
Prior standard of care treatments must include treatment with hormonal therapy in combination with an approved CDK4/6 inhibitor
Patients must have endocrine-resistant disease
Have no known active or symptomatic central nervous system (CNS) disease
Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1
Life expectancy of > 6 months
Eligible to receive fulvestrant
Adequate bone marrow and organ function
Have received chemotherapy, hormonal therapy (with the exception of ongoing LHRH analogs in male patients and premenopausal women), radiation, or biological anti-cancer therapy within 14 days prior to the first dose of NUV-422 and fulvestrant
Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days (of < 5 half-lives) for myelosuppressive agent prior to first dose of NUV-422 and fulvestrant
Moderate liver impairment which would require a reduced dose of fulvestrant
Requires medications that are known to be strong inducers and/or inhibitors of CYP3A4/5 enzymes
For Phase 1b only: requires medications that are known to be moderate inducers and/or inhibitors of CYP3A4/5 enzymes
Known allergy or hypersensitivity to fulvestrant
For Phase 2 only: prior therapy with fulvestrant and/or investigational ER targeted agent
Females who are pregnant or breast feeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Anaheim California, 92801, United States
Fountain Valley California, 92708, United States
Canton Ohio, 44718, United States
Gettysburg Pennsylvania, 17325, United States
Fairfax Virginia, 22031, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.